Related Experiment Video
Updated: Jun 13, 2026
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Enhancement of NK cell antitumor responses using an oncolytic parvovirus
Rauf Bhat1, Sebastian Dempe, Christiane Dinsart
1Division of Tumor Virology, F010, German Cancer Research Center, Heidelberg, Germany. r.bhat@dkfz.de
Abstract:
Natural killer (NK) cells play a vital role in the rejection of tumors. Pancreatic ductal adenocarcinoma (PDAC), however, remains a poor prognosis malignancy, due to its resistance to radio- and chemotherapy, and low immunogenicity. We demonstrate here that IL-2-activated human NK cells are able to kill PDAC cells. Currently, novel strategies are being pursued to combat PDAC. In this regard, oncolytic viruses, in addition to killing tumor cells, may also have the potential to augment antitumor immune responses. We found that, besides having an intrinsic oncolytic activity, parvovirus H-1PV is able to enhance NK cell-mediated killing of PDAC cells. Our results show that H-1PV infection of Panc-1 cells increases NK cell capacity to release IFN-γ, TNF-α and MIP-1α/β. Multiple activating receptors are involved in the NK cell-mediated killing of Panc-1 cells. Indeed, blocking of the natural cytotoxicity receptors-NKp30, 44 and 46 in combination, and NKG2D and DNAM1 alone inhibit the killing of Panc-1 cells. Interestingly, H-1PV infection of Panc-1 cells overcomes the part of inhibitory effects suggesting that parvovirus may induce additional NK cell ligands on Panc-1 cells. The enhanced sensitivity of H-1PV-infected PDAC cells to NK cell-dependent killing could be traced back to the upregulation of the DNAM-1 ligand, CD155 and to the downregulation of MHC class I expression. Our data suggests that NK cells display antitumor potential against PDAC and that H-1PV-based oncolytic immunotherapy could further boost NK cell-mediated immune responses and help to develop a combinatorial therapeutic approach against PDAC.
Insights
Natural killer (NK) cells show potential against pancreatic cancer. Oncolytic parvovirus H-1PV enhances NK cell killing of pancreatic ductal adenocarcinoma (PDAC) cells by altering cell surface ligands, suggesting a new immunotherapy approach.
Area of Science:
- Immunology
- Oncology
- Virology
Background:
- Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy with poor prognosis due to treatment resistance and low immunogenicity.
- Natural killer (NK) cells are crucial for tumor rejection but their efficacy against PDAC is limited.
- Oncolytic viruses are being explored for cancer therapy due to their tumor-lytic activity and potential to stimulate anti-tumor immune responses.
Purpose of the Study:
- To investigate the efficacy of IL-2-activated human NK cells against PDAC cells.
- To evaluate the potential of parvovirus H-1PV as an oncolytic agent to enhance NK cell-mediated killing of PDAC.
- To elucidate the mechanisms by which H-1PV affects NK cell activity and PDAC cell susceptibility.
Main Methods:
- Co-culture of IL-2-activated human NK cells with PDAC cell lines (Panc-1).
- Treatment of PDAC cells with parvovirus H-1PV.
- Assessment of NK cell cytotoxicity, cytokine release (IFN-γ, TNF-α, MIP-1α/β), and receptor involvement (NKp30, 44, 46, NKG2D, DNAM-1).
- Analysis of cell surface marker expression (CD155, MHC class I) on H-1PV-infected PDAC cells.
Main Results:
- IL-2-activated NK cells demonstrated cytotoxic activity against PDAC cells.
- H-1PV exhibited intrinsic oncolytic activity and significantly enhanced NK cell-mediated killing of PDAC cells.
- H-1PV infection upregulated NK cell cytokine production and overcame inhibitory effects by modulating PDAC cell surface ligands, including CD155 upregulation and MHC class I downregulation.
- NK cell-mediated killing involved multiple activating receptors, with DNAM-1 playing a significant role.
Conclusions:
- NK cells possess inherent anti-PDAC potential.
- Parvovirus H-1PV enhances NK cell-mediated anti-PDAC immunity.
- H-1PV-based oncolytic immunotherapy offers a promising strategy for combinatorial treatment of PDAC by boosting NK cell responses.
Related Concept Videos
01:27Tumor Immunotherapy
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
01:29Immune Response Against Viral Pathogens
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
01:28Cells of the Innate Immune Response
Phagocytes
Phagocytes police the peripheral tissues by removing cellular debris and responding to the invasion of foreign substances or pathogens. Many phagocytes attack and remove microorganisms even before lymphocytes detect them. The human body has two general...
01:25Immune Surveillance by NK Cells and Phagocytes
Natural Killer Cells: The Fast Responders
NK cells are large granular lymphocytes found in the blood and lymphatic system. These...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...